Intuitive Surgical Valuation
Is ISRG * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ISRG * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ISRG * (MX$6464.46) is trading above our estimate of fair value (MX$3021.17)
Significantly Below Fair Value: ISRG * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ISRG *?
Other financial metrics that can be useful for relative valuation.
What is ISRG *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$131.84b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 17.4x |
Enterprise Value/EBITDA | 56.1x |
PEG Ratio | 5.8x |
Price to Earnings Ratio vs Peers
How does ISRG *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 38.8x | ||
SYK Stryker | 37x | 10.5% | US$124.8b |
BSX Boston Scientific | 60x | 18.1% | US$106.2b |
MDT Medtronic | 25.6x | 9.7% | US$107.4b |
ABT Abbott Laboratories | 32.8x | 11.3% | US$184.4b |
ISRG * Intuitive Surgical | 67.4x | 11.6% | Mex$131.8b |
Price-To-Earnings vs Peers: ISRG * is expensive based on its Price-To-Earnings Ratio (67.4x) compared to the peer average (38.8x).
Price to Earnings Ratio vs Industry
How does ISRG *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: ISRG * is expensive based on its Price-To-Earnings Ratio (67.4x) compared to the Global Medical Equipment industry average (28x).
Price to Earnings Ratio vs Fair Ratio
What is ISRG *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 67.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ISRG *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$6,464.46 | Mex$7,118.78 +10.1% | 10.7% | Mex$8,043.70 | Mex$4,284.33 | n/a | 24 |
Apr ’25 | Mex$6,575.11 | Mex$6,884.30 +4.7% | 10.5% | Mex$7,896.50 | Mex$4,205.92 | n/a | 25 |
Mar ’25 | Mex$6,612.00 | Mex$6,993.03 +5.8% | 12.1% | Mex$8,132.38 | Mex$3,937.78 | n/a | 25 |
Feb ’25 | Mex$6,503.89 | Mex$6,930.77 +6.6% | 13.9% | Mex$8,174.13 | Mex$3,958.00 | n/a | 25 |
Jan ’25 | Mex$5,685.00 | Mex$5,743.09 +1.0% | 13.2% | Mex$6,812.92 | Mex$3,917.43 | n/a | 25 |
Dec ’24 | Mex$5,507.55 | Mex$5,614.90 +1.9% | 12.7% | Mex$6,876.20 | Mex$3,953.82 | n/a | 25 |
Nov ’24 | Mex$4,663.53 | Mex$5,857.96 +25.6% | 12.8% | Mex$7,211.92 | Mex$4,146.85 | n/a | 24 |
Oct ’24 | Mex$5,124.26 | Mex$6,094.87 +18.9% | 10.5% | Mex$6,736.28 | Mex$3,873.36 | n/a | 23 |
Sep ’24 | Mex$5,315.11 | Mex$6,094.87 +14.7% | 10.5% | Mex$6,736.28 | Mex$3,873.36 | n/a | 23 |
Aug ’24 | Mex$5,470.60 | Mex$6,094.87 +11.4% | 10.5% | Mex$6,736.28 | Mex$3,873.36 | n/a | 23 |
Jul ’24 | Mex$5,793.40 | Mex$5,315.60 -8.2% | 10.5% | Mex$6,249.09 | Mex$3,492.64 | n/a | 21 |
Jun ’24 | Mex$5,452.20 | Mex$5,442.58 -0.2% | 10.1% | Mex$6,445.83 | Mex$3,602.60 | n/a | 21 |
May ’24 | Mex$5,402.77 | Mex$5,488.15 +1.6% | 9.6% | Mex$6,292.97 | Mex$3,667.90 | Mex$6,464.46 | 21 |
Apr ’24 | Mex$4,516.11 | Mex$4,913.47 +8.8% | 11.5% | Mex$5,882.21 | Mex$3,692.22 | Mex$6,575.11 | 21 |
Mar ’24 | Mex$4,083.45 | Mex$5,146.13 +26.0% | 12.3% | Mex$6,108.44 | Mex$3,834.22 | Mex$6,612.00 | 20 |
Feb ’24 | n/a | Mex$5,146.13 0% | 12.3% | Mex$6,108.44 | Mex$3,834.22 | Mex$6,503.89 | 20 |
Jan ’24 | Mex$5,170.00 | Mex$5,358.31 +3.6% | 14.7% | Mex$6,424.89 | Mex$4,032.86 | Mex$5,685.00 | 21 |
Dec ’23 | Mex$4,944.00 | Mex$5,006.71 +1.3% | 13.8% | Mex$6,251.18 | Mex$3,923.82 | Mex$5,507.55 | 20 |
Nov ’23 | Mex$4,830.16 | Mex$5,012.55 +3.8% | 12.4% | Mex$6,456.91 | Mex$4,052.95 | Mex$4,663.53 | 20 |
Oct ’23 | Mex$3,803.11 | Mex$5,030.82 +32.3% | 14.7% | Mex$6,483.62 | Mex$3,491.18 | Mex$5,124.26 | 17 |
Sep ’23 | Mex$4,070.00 | Mex$5,061.65 +24.4% | 14.7% | Mex$6,538.61 | Mex$3,520.79 | Mex$5,315.11 | 17 |
Aug ’23 | Mex$4,591.10 | Mex$5,142.28 +12.0% | 14.7% | Mex$6,650.54 | Mex$3,581.06 | Mex$5,470.60 | 17 |
Jul ’23 | Mex$4,156.00 | Mex$6,281.61 +51.1% | 14.9% | Mex$7,912.64 | Mex$4,086.53 | Mex$5,793.40 | 19 |
Jun ’23 | Mex$4,275.00 | Mex$6,303.74 +47.5% | 13.3% | Mex$7,835.30 | Mex$4,046.58 | Mex$5,452.20 | 19 |
May ’23 | Mex$4,925.78 | Mex$6,565.15 +33.3% | 13.8% | Mex$7,977.89 | Mex$3,675.89 | Mex$5,402.77 | 19 |
Analyst Forecast: Target price is less than 20% higher than the current share price.